Cargando…

HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) remains a global medical problem. Programmed cell death protein 1 (PD-1) is a powerful weapon against many cancers, but it is not sensitive to some patients with HCC. We obtained datasets from the Gene Expression Omnibus (GEO) database on HCC patients and PD-1 immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guoming, Zhang, Cheng, Li, Danyun, Luo, Dongqiang, Liao, Hui, Huang, Peizhen, Wang, Ning, Feng, Yibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953231/
https://www.ncbi.nlm.nih.gov/pubmed/36830729
http://dx.doi.org/10.3390/biom13020360
_version_ 1784893826928738304
author Chen, Guoming
Zhang, Cheng
Li, Danyun
Luo, Dongqiang
Liao, Hui
Huang, Peizhen
Wang, Ning
Feng, Yibin
author_facet Chen, Guoming
Zhang, Cheng
Li, Danyun
Luo, Dongqiang
Liao, Hui
Huang, Peizhen
Wang, Ning
Feng, Yibin
author_sort Chen, Guoming
collection PubMed
description Hepatocellular carcinoma (HCC) remains a global medical problem. Programmed cell death protein 1 (PD-1) is a powerful weapon against many cancers, but it is not sensitive to some patients with HCC. We obtained datasets from the Gene Expression Omnibus (GEO) database on HCC patients and PD-1 immunotherapy to select seven intersecting DEGs. Through Lasso regression, two intersecting genes were acquired as predictors of HCC and PD-1 treatment prognosis, including HAMP and FOS. Logistic regression was performed to build a prediction model. HAMP had a better ability to diagnose HCC and predict PD1 treatment sensitivity. Further, we adapted the support vector machine (SVM) technique using HAMP to predict triple-classified outcomes after PD1 treatment in HCC patients, which had an excellent classification ability. We also performed external validation using TCGA data, which showed that HAMP was elevated in the early stage of HCC. HAMP was positively correlated with the infiltration of 18 major immune cells and the expression of 2 important immune checkpoints, PDCD1 and CTLA4. We discovered a biomarker that can be used for the early diagnosis, prognosis and PD1 immunotherapy efficacy prediction of HCC for the first time and developed a diagnostic model, prognostic model and prediction model of PD1 treatment sensitivity and treatment outcome for HCC patients accordingly.
format Online
Article
Text
id pubmed-9953231
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99532312023-02-25 HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma Chen, Guoming Zhang, Cheng Li, Danyun Luo, Dongqiang Liao, Hui Huang, Peizhen Wang, Ning Feng, Yibin Biomolecules Article Hepatocellular carcinoma (HCC) remains a global medical problem. Programmed cell death protein 1 (PD-1) is a powerful weapon against many cancers, but it is not sensitive to some patients with HCC. We obtained datasets from the Gene Expression Omnibus (GEO) database on HCC patients and PD-1 immunotherapy to select seven intersecting DEGs. Through Lasso regression, two intersecting genes were acquired as predictors of HCC and PD-1 treatment prognosis, including HAMP and FOS. Logistic regression was performed to build a prediction model. HAMP had a better ability to diagnose HCC and predict PD1 treatment sensitivity. Further, we adapted the support vector machine (SVM) technique using HAMP to predict triple-classified outcomes after PD1 treatment in HCC patients, which had an excellent classification ability. We also performed external validation using TCGA data, which showed that HAMP was elevated in the early stage of HCC. HAMP was positively correlated with the infiltration of 18 major immune cells and the expression of 2 important immune checkpoints, PDCD1 and CTLA4. We discovered a biomarker that can be used for the early diagnosis, prognosis and PD1 immunotherapy efficacy prediction of HCC for the first time and developed a diagnostic model, prognostic model and prediction model of PD1 treatment sensitivity and treatment outcome for HCC patients accordingly. MDPI 2023-02-14 /pmc/articles/PMC9953231/ /pubmed/36830729 http://dx.doi.org/10.3390/biom13020360 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Guoming
Zhang, Cheng
Li, Danyun
Luo, Dongqiang
Liao, Hui
Huang, Peizhen
Wang, Ning
Feng, Yibin
HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
title HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
title_full HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
title_fullStr HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
title_full_unstemmed HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
title_short HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
title_sort hamp as a potential diagnostic, pd-(l)1 immunotherapy sensitivity and prognostic biomarker in hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953231/
https://www.ncbi.nlm.nih.gov/pubmed/36830729
http://dx.doi.org/10.3390/biom13020360
work_keys_str_mv AT chenguoming hampasapotentialdiagnosticpdl1immunotherapysensitivityandprognosticbiomarkerinhepatocellularcarcinoma
AT zhangcheng hampasapotentialdiagnosticpdl1immunotherapysensitivityandprognosticbiomarkerinhepatocellularcarcinoma
AT lidanyun hampasapotentialdiagnosticpdl1immunotherapysensitivityandprognosticbiomarkerinhepatocellularcarcinoma
AT luodongqiang hampasapotentialdiagnosticpdl1immunotherapysensitivityandprognosticbiomarkerinhepatocellularcarcinoma
AT liaohui hampasapotentialdiagnosticpdl1immunotherapysensitivityandprognosticbiomarkerinhepatocellularcarcinoma
AT huangpeizhen hampasapotentialdiagnosticpdl1immunotherapysensitivityandprognosticbiomarkerinhepatocellularcarcinoma
AT wangning hampasapotentialdiagnosticpdl1immunotherapysensitivityandprognosticbiomarkerinhepatocellularcarcinoma
AT fengyibin hampasapotentialdiagnosticpdl1immunotherapysensitivityandprognosticbiomarkerinhepatocellularcarcinoma